Hormonal
Incretin therapies are associated with gastrointestinal side effects and potential risks of gallstone disease and pancreatitis, requiring careful patient selection and monitoring, particularly in those with a history of these conditions.
While incretin therapies are effective for MASH, patients should be aware of common side effects like nausea and potential risks like gallstones or pancreatitis. These risks can be managed with slow dose titration, dietary adjustments, and regular monitoring, making the therapy safe for most patients when used appropriately.
Gastrointestinal intolerances (i.e., nausea, vomiting and changes in bowel habits) are the most common side effects reported... The use of incretin drugs may precipitate gallstone disease... Incretin therapies are also associated with elevations in serum amylase and lipase levels... infrequent reports of fatal acute pancreatitis and these agents should be used with caution (or avoided) in people with a history of clinically significant pancreatitis.
Why this rating
Based on consistent reporting of side effects across multiple trials and post-marketing data.
Source
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease
Harendran Elangovan et al. · Hepatology International · 2025
DOI 10.1007/s12072-025-10795-6
More from this paper
- Incretin-based pharmacotherapies (GLP-1, GIP, and triple agonists) significantly improve metabolic dysfunction-associated steatohepatitis (MASH) resolution and fibrosis regression compared to placebo, primarily through weight loss and insulin sensitization, with some agents showing direct hepatic benefits.Good
- Dual and triple receptor agonists (Tirzepatide, Survodutide, Retatrutide) show promise in MASH resolution, with some demonstrating superior efficacy to single GLP-1 agonists in weight loss and MASH resolution, though long-term hepatic outcomes are still being established.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →